leisure time -WSS

leisure time

author：comprehensive 2025-09-30 00:50:53 - browse：51

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

WSS

HHS names first

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Risky weight loss products often used by teens globally, per study

EpiPen alternative approval delay highlights citizen petition issue

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

FDA panel to weigh approval of NurOwn, controversial ALS drug

Wikipedia

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

New Medicare drug pricing powers could soon be upended in court

Trump demands the U.S. pay no more for drugs than other countries … again

Heart disease and mental health: A look at cardiac psychology

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

The nurse manager staffing crisis is hurting patients

Medicare proposal to cover medical devices draws a mixed reaction

STAT Virtual Event: Putting AI to the Test

At least 13 dead in Texas as scorching temps continue

STAT Virtual Event: Putting AI to the Test

focus

Second xenotransplant done with gene

Senate HELP committee spars over health care workforce policies

How AI helped researchers track recovery from depression

Drug for rare kidney disease narrowly misses mark in clinical trial

Risky weight loss products often used by teens globally, per study

Senators: Long

focus

hotspot

hotspot

explore